ClinicalTrials.gg
RecruitingNCT04505618OCTA-RVDUpdated Jun 17, 2026

Optical Coherence Tomography Angiography in Subjects With Retinal Vascular Disease

An interventional study of Swept-Source (SS) OCT Angiography and Spectral-Domain (SD) OCT Angiography in Diabetic Retinopathy, Retinal Vein Occlusion and Hypertension,Essential, sponsored by Johns Hopkins University. Recruiting at 1 site in United States. Open to participants aged 18 Years to 99 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-06-17.

Sponsored by Johns Hopkins University · Not applicable, Interventional, and Screening

How we know

From the registry’s dates

  • Registered 10 months after the study started (first participant enrolled Oct 2019, registered Aug 2020).
  • Started Oct 2019; still recruiting 7 years 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
1,050
Allocation
Non-randomized
Ages
18 Years to 99 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 267 studies in Diabetic Retinopathy with a site in United States — 36 open to participants now, 54 under way, 6 of them phase 3. Diabetic Retinopathy · United States.

Planned enrollment
14th of 196
1,050 · median 72
Started
2019
with 13 others
No phase
53 of 267
10 open now
Primary completion
2027-06
later than 25 of 52 live
Registered
172nd of 267
by date

Among the 267 studies in Diabetic Retinopathy with a site in United States, this one is the 14th largest by planned enrollment of the 196 interventional ones that give a count, is one of 14 that started in 2019, is one of 53 with no phase, reaches primary completion later than 25 of the 52 other live ones, and was the 172nd registered.

Diabetic Retinopathy

783 studies on the registry are indexed under Diabetic Retinopathy; 145 are open to participants now.

Browse Diabetic Retinopathy studies →

Open to participants now

36 of the 267 studies in Diabetic Retinopathy with a site in United States are open now. Recruiting first, the newest first:

31 more — sign in →

All 36 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 93 Diabetic Retinopathy studies recruiting now, 61 (66%) set no upper age limit and 10 (11%) stop at 75 or younger; 8 take children under 18; 30 take healthy volunteers.

This study: 18 Years to 99 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 267 studies in Diabetic Retinopathy with a site in United States, or all of them as a file.
02

Study summary

This study will perform a prospective, longitudinal analysis of clinical and imaging findings from normal controls and subjects with retinal vascular disease to better define the diagnostic imaging criteria that signify change in disease stage. This includes disease progression in early stages of disease or disease regression with appropriate standard-of-care treatment.

Read the detailed description

The objective of this study is to perform a prospective, longitudinal analysis of clinical and imaging findings from normal controls and subjects with retinal vascular disease to better define the diagnostic imaging criteria that signify change in disease stage. This includes disease progression in early stages of disease or disease regression with appropriate standard-of-care treatment.

Subjects will be identified from healthy subjects (seen for screening eye exams) and diseased subjects undergoing standard-of-care treatment or screening at eye clinic locations. The study population will include subjects with retinal vascular disease including but not limited to diabetic retinopathy, hypertension, retinal vein/arterial occlusion, and macular degeneration. Subjects who are enrolled will undergo non-invasive, minimal risk, FDA approved diagnostic imaging procedures to identify vascular changes.

The study methods will include retrospective review and collection of clinically approved imaging data that is obtained through standard-of-care methods for subjects who meet inclusion and exclusion criteria. Subjects who are identified in this manner will be asked to participate in a prospective study by each clinical study site.

The study end-points include the correlation of diagnostic imaging findings from Optical Coherence Tomography (OCT) based images with fundus photographs, clinical disease stage and visual acuity.

03

Conditions studied

  • Diabetic Retinopathy
  • Retinal Vein Occlusion
  • Hypertension,Essential
  • Retinal Vascular Disorder
04

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Exclusion Criteria:

  • Both subjects with diseases and controls:
  • Children (age\<18)
  • Pregnant females
  • Developmentally delayed subjects
  • Subjects unable to provide
  • Inability to cooperate with tests and study instructions
  • Images with motion artifact or signal strength \< 7
  • History of glaucoma
  • History of age-related macular degeneration
  • History of any visually significant eye disease
  • History of proliferative diabetic retinopathy
  • History of any inflammatory disease
  • History of heart disease
  • History of thyroid disease.
  • Additional criteria for controls:
  • History of any type of Diabetes Mellitus
  • History of any type of Hypertension
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Screening
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
1,050 participants (estimated)

Study arms

  • Other
    Controls

    Subjects in this group do not have any ocular pathology and are also not hypertensive. Some subjects in this arm will undergo retinal vascular reactivity assessments.

    Device: Swept-Source (SS) OCT Angiography · Device: Spectral-Domain (SD) OCT Angiography · Device: Fundus Imaging · Device: Axial Length Measurement Device

  • Other
    Diabetics with and without Diabetic Retinopathy Only

    Subjects in this group only have diabetes with or without diabetic retinopathy. Some subjects in this arm will undergo retinal vascular reactivity assessments.

    Device: Swept-Source (SS) OCT Angiography · Device: Spectral-Domain (SD) OCT Angiography · Device: Fundus Imaging · Device: Axial Length Measurement Device

  • Other
    Hypertension Only

    Subjects in this group only have hypertension with or without ocular pathology related to hypertension. Some subjects in this arm may undergo retinal vascular reactivity assessments.

    Device: Swept-Source (SS) OCT Angiography · Device: Spectral-Domain (SD) OCT Angiography · Device: Fundus Imaging · Device: Axial Length Measurement Device

  • Other
    Diabetics w/ or w/o Diabetic Retinopathy & Hypertension

    Subjects in this group have diabetes with or without diabetic retinopathy and hypertension with or without ocular pathology related to hypertension. Some subjects in this arm may undergo retinal vascular reactivity assessments.

    Device: Swept-Source (SS) OCT Angiography · Device: Spectral-Domain (SD) OCT Angiography · Device: Fundus Imaging · Device: Axial Length Measurement Device

Interventions

  • DeviceSwept-Source (SS) OCT Angiography

    Non-invasive, minimal risk, ocular imaging study

    Also known as: SS-OCTA

  • DeviceSpectral-Domain (SD) OCT Angiography

    Non-invasive, minimal risk, ocular imaging study

    Also known as: SD_OCTA

  • DeviceFundus Imaging

    Non-invasive, minimal risk, ocular imaging study

  • DeviceAxial Length Measurement Device

    Non-invasive, minimal risk, ocular imaging study

    Also known as: Intraocular Lens (IOL) Master

06

What researchers measure

Primary outcomes

  1. Correlation of Imaging

    Correlation of diagnostic imaging findings (vessel skeleton density) from OCT based images with disease stage

    Time frame: 5 years

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2019 (actual). Primary completion is estimated for Jun 2027, 92 months after the start.

Of 111 non-industry interventional studies with no phase under Diabetic Retinopathy, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 60. This study's planned 92 months is above that.

Counting every sponsor, half of 126 studies reached it within 29 months; a quarter within 11 and three quarters within 60.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 5, 2020
First posted
Aug 10, 2020
StartActual
Oct 1, 2019
Primary completionEst.
Jun 1, 2027
CompletionEst.
Sep 1, 2027
Last update
Jun 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04505618
Responsible party
Sponsor
First posted
Aug 10, 2020
Start date
Oct 1, 2019
Primary completion
Jun 1, 2027 (estimated)
Completion
Sep 1, 2027 (estimated)
Last update
Jun 17, 2026

Study contacts

Amir H Kashani, MD, PhD
Contact
akashan1@jhmi.edu
410-502-2789
Ana C Martinez, MPH
Contact
acollaz5@jhmi.edu
410-502-2789
Amir Kashani, MD, MPH
principal investigator · Johns Hopkins University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion